ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $51 | +4.1% | 544 | 0.0% | 0.00% | – |
Q2 2023 | $49 | -15.5% | 544 | 0.0% | 0.00% | – |
Q1 2023 | $58 | -99.4% | 544 | +597.4% | 0.00% | – |
Q1 2022 | $9,000 | -10.0% | 78 | 0.0% | 0.00% | – |
Q4 2021 | $10,000 | -16.7% | 78 | 0.0% | 0.00% | – |
Q3 2021 | $12,000 | +20.0% | 78 | 0.0% | 0.00% | – |
Q2 2021 | $10,000 | 0.0% | 78 | 0.0% | 0.00% | – |
Q1 2021 | $10,000 | – | 78 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |